Mitapivat intermediates

 

PYRUKYND (Mitapivat)

CAS RN: 1260075-17-9

Chemical Name:

N-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide

Company: Agios Pharmaceuticals

 

Mitapivat is an orally available, small-molecule, allosteric activator of the red cell isoform of pyruvate kinase (PK-R), with potential to improve hemolytic anemia in patients with pyruvate kinase deficiency (PKD). Upon oral administration, mitapivat binds to and activates PK-R, thereby enhancing glycolytic pathway activity, improving adenosine triphosphate (ATP) levels and reducing 2,3-diphosphoglycerate (2,3-DPG) levels. Mutations in PK-R cause deficiency in PK-R which prevents adequate red blood cell (RBC) glycolysis, leading to a buildup of the upstream glycolytic intermediate 2,3-DPG and deficiency in the PK-R product ATP.

 

 

One synthetic route

Mitapivat intermediates

ethyl 4-aminobenzoate 94-09-7

quinoline-8-sulfonyl chloride 18704-37-5

cyclopropanecarbaldehyde 1489-69-6

piperazine 110-85-0

tert-butyl piperazine-1-carboxylate 143238-38-4

tert-butyl 4-(cyclopropylmethyl)piperazine-1-carboxylate 373608-50-5